In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 501-510

  Barth, V ^a   Need, A B ^a   Tzavara, E T ^b   Giros, B ^b   Overshiner, C ^a   Gleason, S D ^a   Wade, M ^a   Johansson, A M ^a   Perry, K ^a   Nomikos, G G ^a   Witkin, J M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; ACETYLCHOLINE; CHOLINE; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; EPIDEPRIDE; METHYLPHENIDATE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; REBOXETINE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; IN VIVO STUDY; INOTROPISM; ISOTOPE LABELING; LEARNING; MALE; MEMORY DISORDER; MENTAL TASK; MONOTHERAPY; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; TREATMENT OUTCOME;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; DOPAMINE ANTAGONISTS; INDANS; MALE; MICRODIALYSIS; MOLECULAR STRUCTURE; NITRILES; PATTERN RECOGNITION, VISUAL; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDROISOQUINOLINES;

EID: 84872693035     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198895     Document Type: Article

References (45)

1. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, and Phebus LA (2006) Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78:3007-3012.
2. Bombin I, Arango C, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, Gonzalez- Gomez C, Moreno D, Parellada M, Baeza I, and Graell M, et al. (2008) DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and firstepisode psychosis adolescents. Am J Med Genet B Neuropsychiatr Genet 147B: 873-879.
3. Braszko JJ (2010) (1)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats. Eur Neuropsychopharmacol 20:218-225.
4. Bymaster FP, Perry KW, and Wong DT (1985) Measurement of acetylcholine and choline in brain by HPLC with electrochemical detection. Life Sci 37:1775-1781. (Pubitemid 16257063)
5. Chernet E, Martin LJ, Li D, Need AB, Barth VN, Rash KS, and Phebus LA (2005) Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci 78:340-346. (Pubitemid 41599770)
6. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, and Cherezov V, et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-1095.
7. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptormediated behavior. J Pharmacol Exp Ther 314:310-319. (Pubitemid 41058268)
8. Fan X, Bruno KJ, and Hess EJ (2012) Rodent models of ADHD. Curr Top Behav Neurosci 9:273-300.
9. Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Högberg T, Nilsson L, Sjögren I, and Stone-Elander S (1988) Stereoselective binding of 11C-raclopride in living human brain-A search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl) 94:471-4778.
10. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, and Yao BB, et al. (2003) Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 305:897-9078.
11. Gainetdinov RR and Caron MG (2003) Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43:261-284. (Pubitemid 37372642)
12. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, and Huang Y, et al. (2012) Affinity and selectivity of [C]-(1) -PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66:489-500.
13. Giros B, Jaber M, Jones SR, Wightman RM, and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612. (Pubitemid 26052818)
14. Joyce JN, Woolsey C, Ryoo H, Borwege S, and Hagner D (2004) Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2:22.
15. Kapur S, Cho R, Jones C, McKay G, and Zipursky RB (1999) Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol Psychiatry 45:1217-1220. (Pubitemid 29236564)
16. Kiss B, Horti F, and Bobok A (2011) In vitro and in vivo comparison of [ H](1)-PHNO and [ H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D3 from D2 receptor sites. Synapse 65:467-4778.
17. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, and Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28:839-849.
18. Laszy J, Laszlovszky I, and Gyertyán I (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567-575. (Pubitemid 40674757)
19. Levin OS, Nesterova OS, Otcheskaia OV, Zhuravleva EIu, Artemova IIu, Khozova AA, Ismailov AM, Lisenker LN, Vdovichenko TV, and Rotor LD, et al. (2009) [Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 109:36-41.
20. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252. (Pubitemid 27414914)
21. Lumme V, Aalto S, Ilonen T, Någren K, and Hietala J (2007) Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. Psychiatry Res 156:69-74. (Pubitemid 47375070)
22. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, and Wilson AA (2010) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 35:1826-1835.
23. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Di Marzo V, and Drago F (2010) Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res 61:531-536.
24. Micheli F and Heidbreder C (2006) Selective dopamine D3 receptor antagonists: a review 2001-2005. Recent Patents CNS Drug Discov 1:271-2878.
25. Millan MJ and Brocco M (2008) Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) . D(2) antagonist, S33138. Therapie 63:187-229.
26. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804. (Pubitemid 35231256)
27. Need AB, McKinzie JH, Mitch CH, Statnick MA, and Phebus LA (2007) In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/ MS/MS and the administration of three tracers simultaneously. Life Sci 81: 1389-1396. (Pubitemid 47603187)
28. Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, and Skolnick P (2012) Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 84:882-890.
29. Perachon S, Betancur C, Pilon C, Rostène W, Schwartz JC, and Sokoloff P (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport 11: 221-225. (Pubitemid 30053422)
30. Paxinos G and Watson C (1996) The Rat Brain in Stereotaxic Coordinates, 3rd ed, Academic Press, New York.
31. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, and Gentile G, et al. (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (1)-PHNO: Studies in nonhuman primates and transgenic mice. Synapse 63:782-793.
32. Rascol O, Lozano A, Stern M, and Poewe W (2011) Milestones in Parkinson's disease therapeutics. Mov Disord 26:1072-1082.
33. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, and Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165. (Pubitemid 30666872)
34. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, and Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6:329-332.
35. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, and Hornyak M (2011) Levodopa for restless legs syndrome. Cochrane Database Syst Rev 16:CD005504.
36. Shirazi-Southall S, Rodriguez DE, and Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583-594. (Pubitemid 34260977)
37. Sokoloff P, Giros BJ, Martres M-P, Bouthenet ML, and Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
38. Smith AG, Neill JC, and Costall B (1999) The dopamine D3/D2 receptor agonist 7- OH-DPAT induces cognitive impairment in the marmoset. Pharmacol Biochem Behav 63:201-211. (Pubitemid 29234098)
39. Szekeres G, Kéri S, Juhász A, Rimanóczy A, Szendi I, Czimmer C, and Janka Z (2004) Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124B:1-5. (Pubitemid 38031583)
40. Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, and Nomikos GG (2006a) Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 11:187-195. (Pubitemid 43164620)
41. Tzavara ET, Li D, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, and Giros B (2006b) Endocannabinoids activate vanilloid TRPV1 receptors to reduce hyperdopaminergia related hyperactivity: therapeutic implications. Biol Psychiatry 59:508-515. (Pubitemid 43320538)
42. Wadenberg ML, Kapur S, Soliman A, Jones C, and Vaccarino F (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429. (Pubitemid 30470221)
43. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, and Carlsson A (1993). The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94:11-19. (Pubitemid 23330058)
44. Wickens JR, Hyland BI, and Tripp G (2011) Animal models to guide clinical drug development in ADHD: lost in translation? Br J Pharmacol 164:1107-11278.
45. Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, and Gasior M (2004) Protection against cocaine and methamphetamine overdose toxicity in mice by the dopamine D3/D2 agonist R-(1)-trans-3,4a,10b-tetrahydro- 4- propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol. 1 -PD 128,907 J Pharmacol Exp Ther 308:957-964. (Pubitemid 38263971)